Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNA5 | P22460 | 19/20 | 1.00 |
| ▸ | KCNH2 | Q12809 | 16/20 | 1.00 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.90 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.90 |
| ▸ | KCNA3 | P22001 | 1/20 | 0.90 |
| ▸ | CACNA1D | Q01668 | 1/20 | 0.90 |
| ▸ | KCNA1 | Q09470 | 1/20 | 0.90 |
| ▸ | KCND3 | Q9UK17 | 1/20 | 0.90 |
| ▸ | MCHR1 | Q99705 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2884013 | 0.95 | KCNA5 (1.00) | KCNA5KCNH2CYP3A4CYP2C9KCNA3 | |
| SCHEMBL2879810 | 0.95 | KCNA5 (1.00) | KCNA5KCNH2CYP3A4CYP2C9KCNA3 | |
| SCHEMBL2879807 | 0.95 | KCNA5 (1.00) | KCNA5KCNH2CYP3A4CYP2C9KCNA3 | |
| SCHEMBL2880396 | 0.91 | KCNA5 (1.00) | KCNA5KCNH2CYP3A4CYP2C9KCNA3 | |
| SCHEMBL2879818 | 0.90 | KCNA5 (1.00) | KCNA5KCNH2CYP3A4CYP2C9KCNA3 | |
| SCHEMBL2879820 | 0.90 | KCNA5 (1.00) | KCNA5KCNH2CYP3A4CYP2C9KCNA3 | |
| SCHEMBL2887222 | 0.90 | KCNA5 (1.00) | KCNA5KCNH2CYP3A4CYP2C9KCNA3 | |
| SCHEMBL2884464 | 0.90 | KCNA5 (0.90) | KCNA5KCNH2CYP3A4CYP2C9KCNA3 | |
| SCHEMBL2882784 | 0.89 | KCNA5 (1.00) | KCNA5KCNH2CYP3A4CYP2C9KCNA3 | |
| SCHEMBL2886319 | 0.89 | KCNA5 (1.00) | KCNA5KCNH2CYP3A4CYP2C9KCNA3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7803827-B2 | 1-N-amino-2-imidazolidinones and derivatives thereof which are effective as Kv1.5 potassium channel inhibitors providing atrial-selective antiarrhythmic agents; 1-(aminosulfonylamino)-3-[2-(4-methoxyphenyl)ethyl]-4-(3,4-dimethylphenyl)-2-imidazolidinone | WYETH LLC (US) | 2010-09-28 | — | — | US | claimed |
| EP-2035392-A1 | IMIDAZOLE KV1. 5 POTASSIUM CHANNEL INHIBITORS | Wyeth a Corporation of the State of Delaware (US) | 2009-03-18 | — | — | EP | claimed |
| US-7504517-B2 | Kv1.5 potassium channel inhibitors | WYETH (US) | 2009-03-17 | — | — | US | claimed |
| US-20090069342-A1 | KV1.5 POTASSIUM CHANNEL INHIBITORS | WYETH (US) | 2009-03-12 | — | — | US | claimed |
| US-20070299120-A1 | KV1.5 POTASSIUM CHANNEL INHIBITORS | WYETH (US) | 2007-12-27 | — | — | US | claimed |
| WO-2007149874-A1 | IMIDAZOLIDINONE KV1.5 POTASSIUM CHANNEL INHIBITORS | WYETH (US) | 2007-12-27 | — | — | WO | claimed |
| US-7803827-B2 | 1-N-amino-2-imidazolidinones and derivatives thereof which are effective as Kv1.5 potassium channel inhibitors providing atrial-selective antiarrhythmic agents; 1-(aminosulfonylamino)-3-[2-(4-methoxyphenyl)ethyl]-4-(3,4-dimethylphenyl)-2-imidazolidinone | WYETH LLC (US) | 2010-09-28 | — | — | US | disclosed |
| EP-2035392-A1 | IMIDAZOLE KV1. 5 POTASSIUM CHANNEL INHIBITORS | Wyeth a Corporation of the State of Delaware (US) | 2009-03-18 | — | — | EP | disclosed |
| US-7504517-B2 | Kv1.5 potassium channel inhibitors | WYETH (US) | 2009-03-17 | — | — | US | disclosed |
| US-20090069342-A1 | KV1.5 POTASSIUM CHANNEL INHIBITORS | WYETH (US) | 2009-03-12 | — | — | US | disclosed |
| US-20070299120-A1 | KV1.5 POTASSIUM CHANNEL INHIBITORS | WYETH (US) | 2007-12-27 | — | — | US | disclosed |
| WO-2007149874-A1 | IMIDAZOLIDINONE KV1.5 POTASSIUM CHANNEL INHIBITORS | WYETH (US) | 2007-12-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070299120-A1 | KV1.5 POTASSIUM CHANNEL INHIBITORS | KCNJ2, KCNK5, KCNH2 | KCNA5 5/4885KCNH2 3/4885CYP3A4 1139/4885 |
| US-20090069342-A1 | KV1.5 POTASSIUM CHANNEL INHIBITORS | KCNJ2, KCNK5, KCNH2 | KCNA5 5/4885KCNH2 3/4885CYP3A4 1139/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.